Dr Jane Wolstenholme
Jane Wolstenholme
BA(Hons), MSc, PhD
Associate Professor of Health Economics
I have over 25 years of experience in conducting economic evaluations for health policy makers and exploring methodological issues relating to the design and analysis of economic evaluations. I have been a health economist at HERC since 1998, prior to that a research associate at the University of Nottingham.
My research programme has focused on the health economics of cancer, with current research on trial-based evaluations and methodology related to prostate, breast and head and neck cancer. Previous published research relates to the economic evaluation of interventions for prostate, breast, cervical and lung cancer.
My main research interests include designing and conducting economic evaluations alongside trials and cost-effectiveness models. I am principal investigator and co-applicant on a wide variety of funded research projects, across a number of disease areas and health-care technologies, including cancer, chronic kidney disease, obesity, mental health, point of care and in-vitro diagnostics.
I am a senior health economics adviser for the NIHR RSS Research Support Service Hub delivered by University of Southampton and Partners | NIHR and the lead health economist for the NIHR HealthTech Research Centre in Community Healthcare, Oxford University.
I supervise MSc and DPhil students. Examples of current doctoral research:
- Exploring the cost-effectiveness of chronic disease prevention strategies using local area chronic disease scenario modelling.
- Developing a modelling framework for providing individualised estimates of comparative outcomes and cost-effectiveness for competing radiotherapy technologies in cancer patients.
I have published widely and I’m co-author of a major OUP text book ‘Applied Methods of Cost-effectiveness Analysis in Health Care’.
Recent publications
-
Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT.
Hobbs FDR. et al, (2025), Health Technol Assess, 29, 1 - 130
-
Low-dose spironolactone and cardiovascular outcomes in moderate stage Chronic Kidney Disease: a randomised controlled trial
HOBBS R. et al, (2024), Nature Medicine
-
Correction: PET-CT-guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head neck cancer patients (PETNECK2): study protocol for a multicentre feasibility study and non-inferiority, randomised, phase III trial.
Nankivell P. et al, (2024), BMC Cancer, 24
-
NHS reference costs: a history and cautionary note.
Amies-Cull B. et al, (2023), Health Econ Rev, 13
-
Systematic review of patients' and healthcare professionals' views on patient-initiated follow-up in treated cancer patients.
Dretzke J. et al, (2023), Cancer Med, 12, 16531 - 16547